Rigel Pharmaceuticals

To see an up-to date selection of historical analyses and insights on Rigel Pharmaceuticals, visit our new, dynamically updated Company Summary report pages for Rigel Pharmaceuticals.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Rigel Pharmaceuticals are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Rigel Pharmaceuticals, or on any other Company covered by EvaluatePharma® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)
ACR preview – Benlysta and R788 in the spotlight   (Human Genome Sciences)   (Invalid Date)
Therapeutic focus - Second JAK inhibitor enters pivotal trials   (Incyte)   (Invalid Date)
Rigel comes crashing down to earth on RA data   (Rigel Pharmaceuticals)   (Invalid Date)
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent   (Rigel Pharmaceuticals)   (Invalid Date)
Event - Rigel looking strong as second data set approaches   (Rigel Pharmaceuticals)   (Invalid Date)
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial   (Rigel Pharmaceuticals)   (Invalid Date)
Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers   (Rigel Pharmaceuticals)   (Invalid Date)
Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas   (Rigel Pharmaceuticals)   (Invalid Date)

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.